<DOC>
	<DOCNO>NCT00064597</DOCNO>
	<brief_summary>This purpose study develop noninvasive method prenatal diagnosis . Fetal cell find maternal blood . This study design isolate fetal cell sample pregnant woman â€™ blood use cell test fetal chromosome abnormality .</brief_summary>
	<brief_title>Noninvasive Prenatal Diagnosis : Using Fetal Cells From Maternal Blood</brief_title>
	<detailed_description>Fetal cell recover maternal blood , suggest noninvasive prenatal diagnosis possible . However , recovery analysis fetal cell maternal blood complex sensitivity low rarity cell maternal circulation . This study design develop noninvasive , safe , relatively inexpensive , accurate technique prenatal diagnosis genetic disorder first trimester . The study include systematic evaluation variable involve separate enrich fetal cell isolate maternal blood fluorescence activate cell sorting ( FACS ) magnetic activate cell sort ( MACS ) follow fluorescent situ hybridization ( FISH ) chromosome-specific DNA probe . The result test compare obtained amniocentesis chorionic villus sampling ( CVS ) woman . No clinical decision make base result experimental diagnostic/screening technique . Even biological risk associate reproductive genetic technology reduce , possible risk ( benefit ) associate procedure . Some factor may : increase diminish maternal anxiety , increase adjustment maladaption pregnancy , increase feeling coercion undertake procedure , increase decrease comfort reproductive decision-making . The study also assess whether nonbiological psychological effect woman undergo prenatal diagnostic testing . After first five year study , preliminary analysis data show sensitivity aneuploidy detection use fetal cell analysis maternal blood comparable single marker prenatal serum screening , technological advance need fetal cell analysis clinical application part multiple maker method noninvasive prenatal screening . Target cell recovery fetal cell detection well use MACS FACS . The detection rate find least one aneuploid cell case fetal aneuploidy 74.4 % .</detailed_description>
	<mesh_term>Chromosome Disorders</mesh_term>
	<mesh_term>Chromosome Aberrations</mesh_term>
	<criteria>Inclusion Criteria Pregnant Abnormal serum marker profile ( alphafetoprotein , hCG , estriol ) Ultrasound abnormality fetus Any high risk indicator aneuploidy determine physician</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2003</verification_date>
	<keyword>Fetal cell</keyword>
	<keyword>Prenatal diagnosis</keyword>
	<keyword>Cytogenetic disorder</keyword>
	<keyword>Chromosomal disorder</keyword>
	<keyword>Single gene mutation detection</keyword>
	<keyword>Abnormal serum marker profile</keyword>
	<keyword>Fluorescence activate cell sorting ( FACS )</keyword>
	<keyword>Magnetic activate cell sorting ( MACS )</keyword>
	<keyword>Fluorescence situ hybridization ( FISH )</keyword>
	<keyword>Chromosomal disorder fetus</keyword>
	<keyword>Single gene defect fetus</keyword>
</DOC>